Skip to content
Head to head

Disc Medicine vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IRON · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

IRON -16.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (62); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
IRONVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price75.14515.02
Change today-1.27%-1.08%
1-year return-16.8%+22.0%
Market cap$3.42B$130.58B
52-week range40.00 – 99.50412.27 – 568.67
Valuation
P/E (TTM)-11.8533.14
P/E percentile, own 5-yr range46th99th
P/B5.666.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-6.0115.32
Net profit (TTM)$-273.70M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-189.96M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.6%96.8%
Insider activity (12mo)20 buy / 30 sell28 buy / 22 sell
Short interest (% of float)15.5%1.9%
Analyst consensus100% buy (10)95% buy / 5% hold (21)
Analyst price target$125 (+66%)$624 (+21%)
StockVane view
StockVane Quant RatingD (22)C (62)
Company
Employees1556,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.